News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Champions Biotechnology, Inc. (CSBR) Partners with Gradalis Inc. and Mary Crowley Cancer Research Center to Develop Personalized Vaccines for Cancer Patients


2/3/2009 9:37:01 AM

ARLINGTON, Va.--(BUSINESS WIRE)--Champions Biotechnology, Inc. (OTC Bulletin Board: CSBR), a company engaged in the development of advanced preclinical platforms and tumor specific data to enhance the value of oncology drugs, has established a collaboration with Gradalis Inc. and Mary Crowley Cancer Research Center (MCCRC). The team will seek an Investigational New Drug (IND) permission from the U.S. Food and Drug Administration (FDA) to utilize Champions Biotechnology’s Biomerk Tumorgraft™ technology to develop personalized vaccines for cancer patients. Each vaccine is engineered to treat the patient’s specific cancer because it is developed from the patient’s own tumor.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES